Author

Yaolin Pu

Berlin-Brandenburger Centrum für Regenerative TherapienPrimary ORCID profile (0009-0008-7670-4887 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Yaolin PuiD3 papers · Charité – Universitätsmedizin Berlin

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andriko PalmowskiiD· 1 shared Anna Luisa HilleriD· 1 shared Antonia M Klaas· 1 shared Arnd KleyeriD· 1 shared Chantal PichoniD· 1 shared Charlotte Maeve DunneiD· 1 shared David SimóniD· 1 shared Dimitrios L. WagneriD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Andriko PalmowskiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Revisiting the need for mRNA nucleoside modification in CAR T cell engineering

Nourhan Kahwaji, Niklas Kotzian, Jasmin Melissa Prinz, Yaolin Pu, Jonas Kath, Samira Picht, Anna Luisa Hiller, Antonia M Klaas, Charlotte Maeve Dunne, Michael Launspach, Andriko Palmowski, Arnd Kleyer, David Simón, Dimitrios L. Wagner, Chantal Pichon, , Norman Michael Drzeniek

This study shows that unmodified mRNA can be used for CAR-T cell engineering without compromising function, eliminating the need for costly nucleoside modifications.

Molecular Therapy — Nucleic Acids · Jan 5, 2026Peer-reviewedBioengineering